Avadel Pharmaceuticals plc Profile
Industry
Drug Manufacturers - Specialty & GenericSector
HealthcareNumber of Employees
154Avadel Pharmaceuticals's Business Model
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
About Avadel Pharmaceuticals
Website: https://www.avadel.com
CEO (Chief Executive Officer): Mr. Gregory J. Divis Jr.
IPO date: 1996-06-07
Contact
Country: IE
Address: 10 Earlsfort Terrace
City: Dublin
State: None
Phone: 353 1 901 5201
Zip Code: 2
Other
CIK: 0001012477
ISIN: US05337M1045
CUSIP: 05337M104
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
